Respiratory Syncytial Virus Vaccine, Adjuvanted (Arexvy)
Arexvy can be administered to prevent lower respiratory tract disease caused by respiratory syncytial virus in patients age 60 years and older.
The largest reported outbreak of blastomycosis has affected at least 115 employees, contractors, or visitors to a paper mill in the Michigan Upper Peninsula.
Infectious Disease Alert Updates
Immunocompromised Patients with Persistent COVID-19; Endemic Mycoses Are No Longer ‘-Demic’
Inappropriate Antibiotic Prescribing Is Common for Elective Surgeries
A retrospective cohort study of adults who underwent an elective craniotomy, hip replacement, knee replacement, spinal procedure, or hernia repair revealed only 59% adhered to recommended guidelines on prophylactic antibiotic prescribing. Unnecessary vancomycin use was the most common reason for nonadherence and had 19 times higher risk for acute kidney injury.
Preparing for Fresh Concerns of Poliovirus and Acute Flaccid Myelitis
What will be the next health crisis? Could it be wild-type poliovirus, vaccine-derived poliovirus, or the similar condition of acute flaccid myelitis? Are you prepared to recognize and anticipate the complications? The authors prepare clinicians for the acute management of each of these conditions.
RSV Vaccine for Older Patients Receives Support
FDA approved Arexvy to protect people age 60 years and older against the respiratory syncytial virus.
CDC: Be Wary of Travelers From African Outbreaks
Marburg virus has caused outbreaks in two African nations, and healthcare workers should be aware of travel history for incoming patients with classic hemorrhagic fever symptoms.
Healthcare Workers Not Likely Infected, Colonized with C. auris
Recent reports highlighting the continuing increase and geographic spread of Candida auris — a multidrug-resistant fungus that is moving between healthcare facilities — have raised the question of whether healthcare workers could be infected or colonized with the emerging pathogen. It is highly unlikely, but the risk is not zero.
First Oral Fecal Microbiota Product Wins FDA Approval
There is a new tool available in the battle against one of the most common healthcare-associated infections in the United States.
Researchers Use Advanced Technology to Detect MIS-C
Scientists want to improve diagnostic techniques for multisystem inflammatory syndrome in children, which became a confounding problem during the COVID-19 pandemic.